Alimera Sciences

309 articles with Alimera Sciences

• Alimera Sciences Announces Third Quarter 2022 Financial Results

  11/14/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2022.

• Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update

  11/2/2022

  Alimera Sciences, Inc. announces that it will report third quarter financial results on Monday, November 14, 2022, before the market opens.

• Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic

  11/1/2022

  Alimera Sciences, Inc. announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN ® 0.19 mg sustained release intravitreal implant for non-infectious uveitis, through its distribution partner, Medis Pharmaceutical Company.

• Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments

  10/6/2022

  Alimera Sciences, Inc. announced that post-hoc analyses from the PALADIN Phase 4 Safety Study demonstrate that median treatment frequency in diabetic macular edema patients treated with the ILUVIEN® 0.19 mg was lower than from patients on other regimens.

• Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network

  9/23/2022

  Alimera Sciences, Inc. announces that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network.

• Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland

  9/20/2022

  Alimera Sciences, Inc. announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN ® 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Ireland.

• Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

  8/31/2022

  Alimera Sciences, Inc. announces that clinical data for ILUVIEN® 0.19mg will be featured in more than 20 scientific abstracts during the EURETINA 2022 congress being held in Hamburg, Germany from September 1-4, 2022.

• Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

  8/10/2022

  Alimera Sciences, Inc. announced today that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will deliver a corporate presentation at the HC Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17, 2022.

• Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal

  8/9/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Portugal.

• Alimera Sciences Announces Second Quarter 2022 Financial Results

  7/27/2022

  Alimera Sciences, Inc. today announced financial results for the second quarter of 2022.

• Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients

  7/26/2022

  Alimera Sciences, Inc. announced that the PALADIN Phase 4 Study confirms the safety of ILUVIEN® 0.19 mg sustained release intravitreal implant and provides a durable treatment option that reduces the frequency of recurrence for patients with diabetic macular edema.

• Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update

  7/22/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), announces today that it will report second quarter financial results on Wednesday, July 27, 2022, before the market opens.

• Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France Partner Horus Pharma to launch ILUVIEN

  7/22/2022

  Alimera Sciences, Inc. will launch ILUVIEN ® for non-infectious posterior uveitis in France, through its distribution partner, Horus Pharma S.A.S. (Horus).

• Alimera Announces Data to Be Highlighted In Scientific Programming At Annual CongressILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists (ASRS) conference.

  7/13/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that ILUVIEN ® data will be overviewed in various scientific abstracts at the American Society of Retina Specialists (ASRS) conference being held in New York, New York from July 13-16.

• Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

  7/8/2022

  Alimera Sciences, Inc. announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has received approval.

• Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant

  6/8/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), announced today that its partner, Ocumension Therapeutics (“Ocumension”) received approval from the National Medical Products Administration for its IND application to begin the Phase III clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval to treat diabetic macular edema in mainland China.

• Alimera Sciences to Present at the LD Micro Invitational XII Conference

  6/2/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XII Conference. The conference is being held on June 7 – 9, 2022.

• Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes

  5/12/2022

  Alimera Sciences, Inc. announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the ILUVIEN® U.S. label to mitigate the risk of uncontrolled intraocular pressure elevation.

• Alimera Sciences Reports First Quarter 2022 Results

  5/9/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2022.

• Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update

  5/6/2022

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on Monday, May 9, 2022, prior to the market open.